Recently, we have developed and characterized a novel class of selective VEGFR-2/3 inhibitors (4-6). These novel indolyl-and azaindolyl-aryl-maleimides, called Moguntinones, are synthetically designed small molecules, including structural features of 3 natural compounds (combretastatin, rebeccamycin, staurosporin). They showed inhibition of the protein kinases VEGFR-2 and -3, PDGFRβ, FLT3 and GSK3β, anti-angiogenic efficacy and anti-proliferative activity. In addition they induce apoptosis in FLT3-ITD dependent AML cell lines and patient blasts at low micromolar concentrations (7) . While key function of VEGF and PDGF receptors may be clearly attributed to angiogenesis, GSK3β regulates proliferation in a cell type specific manner. One of the important functions of GSK3β is the regulation of transcription factor β-catenin. Phosphorylation of β-catenin by a GSK3β protein complex leads to its ubiquitination and proteosomal degradation thereby abolishing its active role in cell proliferation. GSK3β can be inactivated by protein Disheveled if the Wnt signaling pathway is activated resulting in cell proliferation (8) . But until now the role of GSK3β inhibition (9) is still controversial in a multiplicity of indications and under investigation (10, 11) . FLT3, also known as CD135, binds FLT3 ligands and in turn activates signal transduction molecules regulating cell survival and proliferation in a cell type specific manner.
While function of FLT3 in colorectal cancer remains unclear clinical interest for treatment is based on its immunological function (12) . Injection of FLT-ligands was demonstrated to mobilize dendritic cells resulting in anti-tumor activity of the immune system in patients with colon cancer.
We have selected MOGs for their potential to effectively serve a dual role: inhibition of VEGFR-2/3 as well as cell signaling downstream of GSK3β. Based on our pre-selection process of more than a hundred substances (4-6), two MOGs (MOG 13 and MOG 19), were chosen for further characterization in vitro and in vivo with respect to their potential to treat human colorectal cancer.
Other tested small molecules tyrosine kinase inhibitors to VEGFR and PDGFR like Sunitinib or Sorafenib, though being effective in some indications, cause side effects as hand-foot syndrome and general fatigue (13) . Such side effects were also observed with for instance the novel multikinase inhibitor Regorafinib (VEGFR, TIE-2) in colorectal cancer (14) (15) (16) .
Especially in this indication effective treatment of metastatic disease has also been shown by blockage of intracellular signalling pathways promoting cell growth e. g. by inhibiting EGFR, KRAS and PI3K/mTOR dependent signalling cascades (17) . However, EGFR blocking by monoclonal antibody e. g. Cetuximab or Panitumumab is limited in clinical use for KRAS wild type patients and also by severe side effects (18) . The third approved targeted therapy for colorectal cancer is Bevacizumab, a VEGF binding antibody. Recently, continuation of Bevacizumab after first progression plus standard second-line chemotherapy proved the clinical efficiency of continuous angiogenesis inhibition (19) . With respect to the work presented here it is of special interest that several studies on combination of chemotherapy and different TKI therapy have confirmed a lack of efficacy or increased toxicity. Taken together this demonstrates the need of novel TKI inhibitors with different specificity and the possibility of combination with chemotherapy (20) .
In this manuscript we describe the effects of MOGs on cell signaling and apoptosis in different human colon cancer cell lines versus normal human epithelial cells, as well as in vivo significant anti-angiogenic properties in subcutaneously grown human colon tumors. For summary of key features see Figure 1 and Table 1 .
Material and Methods

Cell culture and authentication of cell lines
The human colorectal cancer cell lines HT-29, HCT-116, Caco-2 and SW480 were obtained Characterization of putative targets (VEGFR2/3, PDGFRβ, FLT3 and GSK3β) in these cell lines were done by RT-PCR as well as FACS (21) and mutational analyses were realized by high resolution melting PCR as described earlier (22) . 
In vitro cytotoxicity and apoptosis assay
The MTT assay was used to measure the effects of the test drugs on cancer tumor cell proliferation (22) . The cells were plated in 96 well plates in different densities, depending on their doubling time, to enable log linear growth for 72 h. Cells were allowed to attach overnight before drugs were added. MOGs were added in final concentrations ranging between 0.01 and 20 µM. Growth inhibition was assessed as inhibitory concentration 50%
(IC 50 ) after 72 h drug exposure to the cells compared with vehicle-treated controls and relative to cell growth at the time of drug addition. Each experiment was performed in triplicate and three independent experiments were performed. non-fat dried milk were exposed for 1 h at room temperature. The ECL chemiluminescence detection kit (Perkin Elmer, Waltham, USA) was used for visualization.
Animals
Female NOD/SCID gc -/-mice were purchased from the central animal facility (ZVTE, University of Mainz, Germany). The mice were maintained in a laminar airflow cabinet under pathogen-free conditions and used at 7-10 weeks of age. Mice were housed in micro-isolator cages with free access to laboratory chow and tap water. All animal experiments were performed in accordance with the UKCCCR regulations for the Welfare of Animals (23) incubation with strepavidin-POD (DAKO, Germany) for 20 min. Antibody binding was visualized using DAB-solution (DAKO, Germany). Finally, the tissues were counterstained by haemalaun solution (DAKO, Germany).
Statistical analysis
Significant effects between treatment groups or between treatment groups and control were accomplished by using the two-sample Student's t-test using SPSS statistical analysis software. For more than two independent samples, the total significance level a = 0.05 was Bonferroni adjusted for each pairwise test. Results are expressed as mean standard deviation (SD). p values < 0.05 were considered to indicate significant differences. 
Results and discussion
Out of over a hundred different derivatives MOG 13 and 19 were selected as potent inhibitors of vessel growth in HET-CAM assay as well as having sub-nanomolar IC 50 values for the inhibition of VEGFR-2/-3, PDGFRβ and FLT3 in a kinase screen (see Figure 1 and Table 1, Ref. (5) and (4) 
The cytotoxic activity and apoptosis induction of MOG 19 and 13 was assayed using MTT and propidium iodide assays (see Fig.2 and supplementary Fig. 2 C) . MOG 19 did not show cytotoxic activity in the dose range tested up to 20 µM after three days drug exposure in all cancer and two normal human colon cell lines. Only the human epithelial cell line HCoEpiC indicated a concentration-dependent reduction of viability starting up 1 µM. In contrast MOG 13 showed a concentration-dependent cytotoxicity, which was also cell line dependent.
SW480 was the most sensitive with a reduction of viable tumor cells to 40% at 1 µM MOG 13 compared to the vehicle control (Fig. 2, IC (29) and cyclins for cell cycle (30) . Their activation resulted in the observed G1 arrest and in the combination treatment the induced apoptosis. Other GSK3β inhibitors e. g. Luteolin leads also to de-phosphorylation and activation of GSK3β (31) . The activated protein then targeted cyclin D1 and induces G1 arrest. GSK3β, as a multi-player in cell metabolism, represents a promising therapeutic target. It has been shown to play an important role in the determination of cyclin D1 expression level by regulating mRNA transcription and protein degradation (30) . In lung cancer, the modulation of GSK3β/β-catenin pathway inhibited angiogenesis and proliferation (32) . Also in HUVEC, the inhibition of Akt/GSK3β and mTOR signaling led to a suppression of angiogenesis in vitro and in vivo (33) This small molecule exhibits comparable MOG targets (36) and is the first multikinase inhibitor with survival benefits for metastatic colorectal cancer that will be approved by the 
